Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Enters into $475M Financing Agreement
Summary
On May 13, 2024, Apellis Pharmaceuticals, Inc. entered into a financing agreement with Sixth Street Lending Partners for a senior secured term loan facility of up to $475 million. The initial draw of $375 million was used to buy out remaining obligations owed to SFJ Pharmaceuticals, eliminating $366 million in future payments. The Credit Facility matures on May 13, 2030, and includes customary covenants and conditions.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement